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Liposomes were first described by British haematologist 
Dr Alec D Bangham FRS in 1961, observed from electron 
microscope by adding negative stain to dry phospholipids. 
The name liposome is derived from two Greek words: 
'Lipos' meaning fat and 'Soma' meaning body1When 
phospholipids are dispersed in water, they spontaneously 
form closed structure with internal aqueous environment 
bounded by phospholipid bilayer membranes, this 
vesicular system is called as liposome.2 
Liposomes are micro-particulate or colloidal carriers, 
usually 0.05-5.0 µm in diameter which form spontaneously 
when certain lipids are hydrated in aqueous media 
3Liposomes are composed of relatively bio-compatible and 
biodegradable material, and they consist of an aqueous 
volume entrapped by one or more bilayers of natural and 
/or synthetic lipids. Drugs widely varying lipophilicites 
can be encapsulated in liposomes, either in the 
phospholipid bilayer, in the entrapped aqueous volume or 
at the bilayer interface. Liposomes have been investigated 
as carriers of various pharmacologically active agents such 
as antineoplastic and anti-microbial drugs, chelating 
agents, steroids, vaccines and genetic material 4  
Due to recent developments in liposome technology more 
effective strategies are now available for controlling the 
stability and reactivity of liposomes after systemic 
administration 5 On the basis of the ability of liposomes to 
interact with cells or blood components, at least two types 
of liposome currently can be designed including: 1) non-
interactive sterically stabilised (long circulating) liposomes 
(LCL) and 2) highly interactive cationic liposomes. 
Sterically stabilised liposomes can be formulated by 
incorporating hydrophilic long chain polymers in the 
bilayer which can form a coat on the liposome surface and 
repel opsonin penetration and adsorption. 
ADVANTAGES 
 Provide controlled drug delivery 
 Biodegradable, biocompatible, flexible 
 Can carry both water and lipid soluble drugs 
 Drugs can be stabilized from oxidation 
 Improve protein stabilization 
 Provide sustained release 
 Targeted drug delivery or site specific drug delivery 
 Alter pharmacokinetics and pharmacodynamics of 
drug 
CLASSIFICATION OF LIPOSOMES 
On The Basis Of Composition 
Liposomes are composed of natural or synthetic lipids 
(phospho- and sphingo-lipids,) and may also contain other 
bilayer constituents such as cholesterol and hydrophilic 
polymer conjugated lipids. The net physiochemical 
properties of lipids composing the liposomes, such as 
membrane fluidity, charge density, steric hindrance, and 
permeability, determine liposomes interactions with blood 
components and other tissues after systemic 
administration. The nature and extent of liposomes –cell 
interaction in turn determines the mode of intracellular 
delivery of drugs. Thus, the predominant mechanism 
behind intracellular delivery of drugs by liposomes may 
mainly depend on their composition. 
Liposomes can be classified in terms of composition and 
mechanism of intracellular delivery into five types as: 
1. Conventional liposomes  
2. pH sensitive liposomes 
3. Cationic liposomes 
4. Immune liposomes 
5. Long circulating liposomes  
On The Basis of Size 
The liposome size can vary from small (0.025µm) to large 
(2.5 µm) vesicles. Furthermore, liposomes may have single 
multiple bilayer membranes. The vesicle size is a critical 
parameter in determining circulation half-life of 
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liposomes; both size and number of bilayers influence the 
extent of drug encapsulation in the liposomes. On the basis 
of their size and number of bilayers, liposomes can be 
classified into one of the categories: 
1. Multi lamellar vesicles (MLV) 
2. Large uni lamellar vesicles (LUV) 
3. Small uni lamellar vesicles (SUV) 
METHODS OF LIPOSOMES PREPARATION 
Liposomes of different sizes and characteristics usually 
require different methods of preparation. The most simple 
and the widely used method for preparation of MLV is the 
thin film hydration procedure in which an aqueous buffer 
at a temperature of lipids.  The drug to be encapsulated is 
included either in the aqueous hydration buffer (for 
hydrophilic drugs) or in the lipid film (for lipophilic 
drugs). Thin –film hydration method produces a 
heterogeneous population of MLV (1-5 diameter ) which 
can be sonicated or extruded through polycarbonate filters 
to produce small (up to 0.025 m) and more uniformly sized 
population of SUV . 
Although thin –film hydration is a simple technique, one 
of the major advantages of this method is its relatively 
poor encapsulation efficiency (5-15 %) of hydrophilic 
drugs moreover, reduction of liposomes further decreases 
the amount of encapsulated drug. MLV with high 
entrapment efficiency (up to 40%) can be prepared by 
freeze – drying performed SUV dispersion in an aqueous 
solution of the drug to be encapsulated 6. The encapsulated 
efficiency of MLV can also be increased by hydrating lipid 
in the presence of organic solvent. 7 
Several methods have been developed for the preparation 
of large unilamellar vesicles (LUV), including solvent 
(either or ethanol) injection, detergent dialysis, calcium 
induced fusion, and reverse – phase evaporation (REV) 
techniques. SUV can be prepared from MLV or LUV by 
sonication (using probe sonicator) or extrusion (passage 
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 Lipid film hydration by hand  1.Ethanol injection     1.detergent Removal fromMixed micelles 
 Shaking, on-hand shaking  2.Ether injection.   by: Dialysis. 
 Or freeze drying.   3. Double emulsion.  Dilution.      
 Micro-emulsification.  4.Riverse phase      Column-chromatography 
 Sonication.      -evaporation vesicles.    
 French pressure cell.  5. Stable pluri lamellar    
 Membrane extrusion.       Vesicles.    
 Dried reconstituted     
 Vesicles.         
 Freeze-thawed liposomes.       
 
Figure 1: Shows Different schematic method of liposome preparations 
METHODS OF LIPOSOME  
 PREPARATION 
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I.MECHANICAL DISPERSION METHODS 
1. Preparation of liposomes by lipid film hydration 
Preparation of Lipid for Hydration 
When preparing liposomes with mixed lipid composition, 
the lipids must first be dissolved and mixed in an organic 
solvent to assure a homogeneous mixture of lipids. Usually 
this process is carried out using chloroform or chloroform: 
methanol mixtures. 
.  
Figure 2:  Liposomes prepared by thin layer 
evaporation technique. 
The intent is to obtain a clear lipid solution for complete 
mixing of lipids. Typically lipid solutions are prepared at 
10-20mg lipid/ml of organic solvent, although higher 
concentrations may be used if the lipid solubility and 
mixing are acceptable. Once the lipids are thoroughly 
mixed in the organic solvent, the solvent is removed to 
yield a lipid film. For small volumes of organic solvent 
(<1mL), the solvent may be evaporated using a dry 
nitrogen or argon stream in a fume hood. For larger 
volumes, the organic solvent should be removed by rotary 
evaporation yielding a thin lipid film on the sides of a 
round bottom flask. The lipid film is thoroughly dried to 
remove residual organic solvent by placing the vial or flask 
on a vacuum pump overnight. If the use of chloroform is 
objectionable, an alternative is to dissolve the lipid(s) in 
tertiary butanol or cyclohexane. The lipid solution is 
transferred to containers and frozen by placing the 
containers on a block of dry ice or swirling the container in 
a dry ice-acetone or alcohol (ethanol or methanol) bath. 
Care should be taken when using the bath procedure that 
the container can withstand sudden temperature changes 
without cracking. After freezing completely, the frozen 
lipid cake is placed on a vacuum pump and lyophilized 
until dry (1-3 days depending on volume). The thickness 
of the lipid cake should not be more than the diameter of 
the container being used for lyophilisation. Dry lipid films 
or cakes can be removed from the vacuum pump, the 
container should be closed tightly and taped, and stored 
frozen until ready to hydrate.15 
2. Sizing of Lipid Suspension 
Disruption of LMV suspensions using sonic energy 
(sonication) typically produces small, unilamellar vesicles 
(SUV) with diameters in the range of 15-50nm. The most 
common instrumentation for preparation of sonicated 
particles is bath and probe tip sonicators. Cup-horn 
sonicators, although less widely used, have successfully 
produced SUV. Probe tip sonicators deliver high energy 
input to the lipid suspension but suffer from overheating of 
the lipid suspension causing degradation. Sonication tips 
also tend to release titanium particles into the lipid 
suspension which must be removed by centrifugation prior 
to use. For these reasons, bath sonicators are the most 
widely used instrumentation for preparation of SUV. 
Sonication of an LMV dispersion is accomplished by 
placing a test tube containing the suspension in a bath 
sonicator (or placing the tip of the sonicator in the test 
tube) and sonicating for 5-10 minutes above the Tc of the 
lipid. The lipid suspension should begin to clarify to yield 
a slightly hazy transparent solution. The haze is due to 
light scattering induced by residual large particles 
remaining in the suspension. These particles can be 
removed by centrifugation to yield a clear suspension of 
SUV. Mean size and distribution is influenced by 
composition and concentration, temperature, sonication 
time and power, volume, and sonicator tuning. Since it is 
nearly impossible to reproduce the conditions of 
sonication, size variation between batches produced at 
different times is not uncommon. Also, due to the high 
degree of curvature of these membranes, SUV are 
inherently unstable and will spontaneously fuse to form 
larger vesicles when stored below their phase transition 
temperature 
3. French Pressure Cell Method 
The method involves the extrusion of MLV at 20,000 psi 
at 4°C through a small orifice. The method has several 
advantages over sonication method. The method is simple, 
rapid, and reproducible and involves gentle handling of 
unstable materials (Hamilton and uo, 1984). The resulting 
liposomes are somewhat larger than sonicated SUVs. The 
drawbacks of the method are that the temperature is 
difficult to achieve and the working volumes are relatively 
small (about 50 mL maximum). 16 
 
 
Figure 3: Liposomes prepared by French Pressure Cell Method 
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II. METHODS BASED ON REPLACEMENT OF 
ORGANIC SOLVENTS 
In this method lipids are co-solvated in organic solution, 
which is then dispersed into aqueous phase containing 
material to be entrapped within the liposome. This method 
is of two types: 
1. Reverse Phase Evaporation 
The lipid mixture is added to a round bottom flask and the 
solvent is removed under reduced pressure by a rotary 
evaporator. The system is purged with nitrogen and lipids 
are re-dissolved in the organic phase which is the phase in 
which the reverse phase vesicle ill form. Diethyl ether and 
isopropyl ether are the usual solvents of choice. After the 
lipids are redissolved the emulsion are obtained and then 
the solvent is removed from an emulsion by evaporation to 
a semisolid gel under reduced pressure. Non encapsulated 
material is then removed. The resulting liposomes are 
called reverse phase evaporation vesicles (REV). This 
method is used for the preparation of large uni-lamellar 
and oligo-lamellar vesicles formulation and it has the 
ability to encapsulate large macromolecules with high 
efficiency. 17 
From observation of the phospatidylcholine cholesterol 
liposomes containing amphotericin B prepared by reverse 
phase evaporation method, the liposomes containing 
amphotericin B 2.0 mol % of total lipid demonstrated the 
highest percentage of drug entrapment, highest drug 
entrapment efficiency (approx. 95%) with particle size 
range of 1307- 1451 nm was obtained with the formulation 
containing 1:1 molar ratio of phosphatidycholine to 
cholesterol[18 
2. Ether Vaporization Method 
There are two methods according to the solvent used: 
 Ethanol injection method. 
 Ether injection method. 
In ethanol injection method, the lipid is injected rapidly 
through a fine needle into an excess of saline or other 
aqueous medium. In ether injection method the lipid is 
injected very slowly trough a fine needle into an excess of 
saline or other aqueous medium. 
III. METHODS BASED ON SIZE 
TRANSFORMATION OR 
FUSION OF PREFORMED VESICLE 
1. The Dehydration- Rehydration Method 
In this method the empty buffer containing SUVs and 
rehydrating it with the aqueous fluid containing the 
material to be entrapped after which they are dried. This 
leads to a dispersion of solid lipids in finely subdivided 
form. Freeze drying is often the method of choice. The 
vesicles are than rehydrated. Liposomes obtained by this 
method are usually oligolamellar vesicle. 
19
 
Liposome prepared by the conventional thin film hydration 
technique, 20 the result showed that the formation of bi-
layered liposomes in the particle size range of 0.2-0.8276 
occurred with a maximum entrapment efficiency of 42.6% 
and the liposomes stored at 4-5oC showed maximum 
stability as compared to those stored at any other 
temperature. 
CHARACTERIZATION OF LIPOSOMES  
Evaluation could be classified into three broad categories 
which are physical, chemical and biological methods. The 
physical methods include various parameters, which are 
size, shape, surface features, lamellarity phase behaviours 
and drug release profile. 
Structural integrity of liposomal phospholipids membrane 
by a new technique of gamma-ray perturbing Sular 
correlation (PAC) spectroscopy. In this In-label 
diethyenetriaminepentaaceticacid (DTPA) derivative 
dipalmitoylphosphatidyl ethanolamine (DPPE) lipid were 
incorporated in the SUVs. This helped in the continuous 
non- invasive monitoring of the microenvironment of the 
lipid bilayer.  
Quasi elastic light scattering (QELS) or photon correlate 
spectroscopic (PCS) technique for determining distribution 
of vesicles prepared by freeze-thaw extrusion method.22 
The influence of filter pore size, extrusion press and lipid 
concentration on the size and size distribution extruded 
vesicles was studied.  
Chemicalcharacterization includes those studies which 
established the purity and potency of various liposomal 
constituents. 
Biological characterization is helpful in establishing the 
safety  and suitability of formulation for the in vivo use for 
therapeutic application 23.The characteristics of the carrier 
through appropriate choice of membrane components, size 
and charge determines the final behaviour of liposomes 
both in vitro and in vivo as well24,25 Characterized vesicles 
are obtained by repetitive extrusion through polycarbonate 
membranes using freeze fracture electron microscopy, 
small angle X-ray scattering (SAXS), and encapsulated 
volume using 6-carboxy fluroescein (6-CF) and 31p-NMR 
as aqueous markers. 26  
CHARACTERIZATION OF LIPOSOMES WITH 
THEIR QUALITY CONTROL ASSAYS 
27-45 
Table 1: Biological characterization of Liposomes 
Characterization parameters Instrument for analysis 
Sterility Aerobic/anaerobic culture 
Pyrogenicity Rabbit fever response 
Animal toxicity Monitoring survival rats 
      
Table 2: Chemical characterization of Liposomes 
Characterization 
parameter 
Instrument for analysis 
Phospholipids concentration HPLC/Barrlet assay 
Cholesterol concentration HPLC / cholesterol oxide 
assay 
Drug concentration Assay method 
Phospholipids per oxidation UV observance 
Phospholipids hydrolysis HPLC/ TLC 
Cholesterol auto-oxidation HPLC/ TLC 
Anti-oxidant degradation HPLC/TLC 
PH PH meter 
Osmolarity Osmometer 
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Table 3.Physical Characterization of Liposomes 
Characterization parameter Instrument for analysis 
Vesicle shape, and surface morphology TEM and SEM 
Vesicle size and size distribution Dynamic light scattering ,TEM 
Surface charge Free flow electrophoresis 
Electrical surface potential and surfacePH Zeta potential measurement and PHsensitive probes 
Lamellarity P31NMR 
Phase behaviour DSC, freeze fracture electron microscopy 
Percent capture Mini column centrifugation, gel exclusion 
Drug release Diffuse cell/ dialysis 
       
STABILIZATION OF LIPOSOME 
The stability of liposome should meet the same standard as 
conventional pharmaceutical formulation. The stability of 
any pharmaceutical product is the capabilities of the 
delivery system in the prescribed formulation to remain 
within defined or pre established limits for predetermined 
period of time. Chemical stability involves prevention of 
both the hydrolysis of ester bonds in the phospholipids 
bilayers and the oxidation of unsaturated sites in the lipid 
chain. Chemical instability leads to physical instability or 
leakage of encapsulated drug from the bilayers and fusion 
and finally aggregation of vesicles.46  
The pro-liposome concept of liposome preparation was 
introduced to avoid physicochemical instability 
encountered in liposome suspension such as aggregation, 
fusion, hydrolysis, and/or oxidation.47 
Approaches that can be taken to increase liposomal 
stability involve efficient formulation and lyophilisation. 
Formulation involves the selection of the appropriate lipid 
composition, concentration of bilayers, aqueous phase 
ingredients such as buffers, antioxidant, metal chelators 
and cryo protectants. Charge inducing lipid such as 
phosphotidyl glycerol can be incorporated into liposome 
bilayers to decrease fusion while cholesterol and 
sphingomyellin can be included in the formulation to 
decrease permeability and leakage of encapsulated drugs. 
Buffers at neutral pH can decrease hydrolysis; addition of 
antioxidant such as sodium ascorbate can decrease 
oxidation. Oxygen potential is kept to minimum during 
processing by nitrogen purging solution.48 
In general successful formulation of stable liposomal drug 
product requires the following precautions: 
1. Processing with fresh, purified lipids and solvents. 
2. Avoidance of high temperature and excessive shear 
forces 
3. Maintenance of low oxygen potential (Nitrogen 
purging) 
4. Use of antioxidant or metal chelators 
5. Formulating at neutral pH. 
6. Use of lyo-protectant when freeze drying 
APPLICATION OF LIPOSOMES 
A. Liposome for Respiratory Drug Delivery System 
Liposome is widely used in several types of respiratory 
disorders. Liposomal aerosol has several advantages over 
ordinary aerosol which are as follows 49 
1. Sustained release 
2. Prevention of local irritation 
3. Reduced toxicity and 
4. Improved stability in the large aqueous core. 
Several injectable liposome based product are now in the 
market including ambisome, fungisome and Mycoses. To 
be effective, liposomal drug delivery system for the lung is 
dependent on the following parameters: 
1. Lipid composition 
2. Size 
3. Charge 
4. Drug and Lipid ratio and 
5. Method of delivery 
Table 4: Liposomal Formulation for the Respiratory Disorder
50 
Active constituent Effect 
Insulin Isoniazid and Rifampicin 
Catalase Conferred resistance to pulmonary oxygen toxicity 
Super oxide dusmutase Minimize toxicity to subsequent hyperoxia and improvedSurvival 
Cyclosporins Preferentially adsorbed by lung and shows sustainedRelease 
Ricins vaccine Improved safety profile for intra pulmonary vaccination 
Interleukin-2 The lungs Facilitated bioactivity and reduce toxicity 
Isoniazid and Rifampicin Improved the effect of drugs for the tuberculosis 
       
B. Liposomes for Brain Targeting drug delivery 
The biocompatible and biodegradable behaviour of 
liposomes have recently led to their exploration as drug 
delivery system to brain. 51Liposomes with a small 
diameter (100 nm) as well as large diameter undergo free 
diffusion through the Blood Brain Barrier (BBB). 
However it is possible that a small unilamellar vesicles 
(SUVS) coupled to brain drug transport vectors may be 
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transported through the BBB by receptor mediated or 
absorptive mediated transcytosis. Similarly, cationic 
liposomes which were developed recently showed these 
structures to undergo absorptive mediated endocytosis into 
cells. Whether cationic liposomes successfully undergo 
absorptive mediated transcytosis through the BBB has not 
yet been determined. The transport of substances through 
BBB by liposomes was extensively studied. The important 
finding issues from their studies are that the addition of the 
sulphatide (a sulphur ester of galactocerebroside) to 
liposome composition increases their several recent 
applications ability to cross BBB 52. Liposomes coated 
with the mannose reach brain tissue and the mannose coat 
assist transport of loaded drug through BBB 53. The 
neutropeptides, leu-enkephaline and 
mefenkephalinkyoforphin normally do not cross BBB 
when given systemically. The anti depressantamitriptylline 
normally penetrate the BBB, due to versatility of this 
method. Nanoparticles (NP) were fabricated with different 
stabilizers. It was found that amitriptyline level was 
significantly enhanced in brain when the substance was 
adsorbed onto the NP and coated or particle stabilized with 
polysorbate 85. 54 
C. Liposome in Tumour Therapy 
The long term therapy of anticancer drug leads to several 
toxic side effect. The liposomal therapy for the targeting to 
the tumour cell have been revolutionized the world of 
cancer therapy with least side effect. It has been said that 
the small and stable liposome are passively targeted to 
different tumour because they can circulate for longer time 
and they can extra vasate in tissue with enhanced vascular 
permeability. 55, 56. 
NEW GENERATION LIPOSOMES 
 Virosomes. 
 Magnetic liposomes. 
 ATP liposomes. 
 Liposomes in photodynamic delivery. 
 Cytoskeleton-specific immune-liposomes 
 Liposomal haemoglobin. 
CONCLUSION 
In summary, this article reviewed the possible applications 
of liposomes and discussed in brief about some problems 
associated with formulation and development. Liposomes 
are prepared by various methods in which the most 
common methods applied for research purpose are film 
and dehydration rehydration methods. Stabilization of 
liposomes has been an area of concern for optimum shelf 
life of the liposomal formulation. Nowadays, stealth 
liposome (Pegylated liposome) is under development, with 
prolonged circulation and residence time in the body. The 
new developments in the liposome are the specific binding 
properties of a drug-carrying liposome to a target cell 
(tumour cell and specific molecules), stealth liposomes for 
targeting hydrophilic (water soluble) anticancer drugs like 
doxorubicin, Mitoxantrone which leads to decrease in side 
effects because the drug is mostly concentrated at the site 
of action. Other development is bisphosphonate-liposome 
mediated depletion of macrophages. Several commercial 
liposomes have already been discovered, registered and 
introduced with great success in pharmaceutical market. 
There is even greater promise in future for marketing of 
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